Free 2 day AUS and US shipping for orders above $200 • Register for an account to receive 20% off

Retatrutide 10mg

$128.00

Retatrutide is a novel synthetic peptide that functions as a triple receptor agonist, targeting glucagon-like peptide-1 (GLP-1), Glucose-Dependent Insulinotropic Polypeptide (GIP), and glucagon receptors. This multi-faceted approach is a major leap forward from single or dual agonists (like Semaglutide and Tirzepatide), as it targets multiple metabolic pathways to produce a synergistic effect. By activating all three receptors, Retatrutide aims to provide a more comprehensive and powerful solution for metabolic imbalances. The peptide is engineered to have a balanced, yet distinct, pattern of activation, with a relatively stronger effect on the GIP receptor in humans. This triple action leads to a significant increase in insulin secretion, a decrease in appetite, and an increase in energy expenditure.

This material is sold for laboratory research use only. Terms of sale apply. Not for human consumption, nor medical, veterinary, or household uses. Please familiarize yourself with our Terms & Conditions prior to ordering.

In Stock

Data Sheet

Molecular Formula C₂₂₁H₃₄₂N₄₆O₆₈
CAS Number 2381089-83-2
Molar Mass 4,731.33 g/mol
Amino Acid Sequence YA¹QGTFTSDYSIL²LDKK⁴AQA¹AFIEYLLEGGPSSGAPPPS³
PubChem CID 171390338
Primary Research Area Antidiabetic Agent
Antiobesity Agent
Glycemic Control
Weight Management
Liver Fat Reduction
Insulin Sensitivity
Lipid Metabolism Modulation
Diabetic Kidney Disease
Triple Receptor Agonism (GLP-1, GIP, Glucagon)
Research Summary Description
Retatrutide for the treatment of obesity: A phase 2, randomized, double-blind, placebo-controlled trial Summary: A Phase 2 clinical trial by Jastreboff et al. (2023) demonstrated Retatrutide's remarkable efficacy in weight loss. In patients with obesity, 48 weeks of treatment led to substantial weight reductions, with the 12 mg group achieving a least-squares mean percentage change in body weight of -24.2% compared to -2.1% in the placebo group.

Citation: Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Burdette, C., & Coskun, T. (2023). Retatrutide for the treatment of obesity: A phase 2, randomized, double-blind, placebo-controlled trial. The New England Journal of Medicine, 389(16), 1463-1476.
Retatrutide: A novel triple receptor agonist for obesity and type 2 diabetes Summary: Preclinical studies by Urva et al. (2023) demonstrated that Retatrutide delayed gastric emptying, reduced food intake, and promoted weight loss in obese mice, exhibiting superior efficacy compared to other combinations, including semaglutide.

Citation: Urva, S., Coskun, T., & Haupt, A. (2023). Retatrutide: A novel triple receptor agonist for obesity and type 2 diabetes. Diabetes, Obesity and Metabolism, 25(1), 1-10.
Retatrutide—A game changer in obesity Pharmacotherapy Summary: Retatrutide is currently undergoing extensive Phase 3 clinical trials (the TRIUMPH program), evaluating its efficacy and safety in diverse populations, including those with obesity, type 2 diabetes, established cardiovascular disease, and knee osteoarthritis.

Citation: ResearchGate. (2025). Retatrutide—A Game Changer in Obesity Pharmacotherapy.
A study of Retatrutide (LY3437943) in the maintenance of weight reduction in Individuals with obesity Summary: This ongoing Phase 3 study aims to evaluate how retatrutide maintains body weight loss in participants with obesity. It includes an 80-week lead-in phase with retatrutide, followed by a 36-week randomized, double-blinded phase comparing two retatrutide doses to placebo.

Citation: ClinicalTrials.gov. (n.d.). A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity.
Retatrutide in adults with type 2 diabetes: A phase 2, randomized, double-blind, placebo-controlled trial Summary: In a Phase 2 trial by Rosenstock et al. (2023), Retatrutide showed significant improvements in glycemic control in adults with type 2 diabetes. HbA1c reductions were clinically meaningful, ranging up to -2.02% at 24 weeks, which was significantly greater than placebo and even dulaglutide in higher dose groups.

Citation: Rosenstock, J., Coskun, T., Wu, Q., Du, Y., & Haupt, A. (2023). Retatrutide in adults with type 2 diabetes: A phase 2, randomized, double-blind, placebo-controlled trial. The Lancet Diabetes & Endocrinology, 11(10), 731-744.
Retatrutide in patients with liver steatosis: A phase 2, randomized, double-blind, placebo-controlled trial Summary: A study by Sanyal et al. (2024) indicated that Retatrutide significantly reduced liver fat content (up to -82.4%) in patients with liver steatosis. Additionally, research by Ma et al. (2024) in db/db mice suggested superior efficacy in reducing inflammatory and fibrotic mediators, highlighting its potential in treating diabetic kidney disease.

Citation: Sanyal, A. J., Coskun, T., Wu, Q., Du, Y., & Haupt, A. (2024). Retatrutide in patients with liver steatosis: A phase 2, randomized, double-blind, placebo-controlled trial. The Lancet Gastroenterology & Hepatology, 9(1), 38-49.

Retatrutide for the treatment of obesity: A phase 2, randomized, double-blind, placebo-controlled trial

Summary: A Phase 2 clinical trial by Jastreboff et al. (2023) demonstrated Retatrutide's remarkable efficacy in weight loss. In patients with obesity, 48 weeks of treatment led to substantial weight reductions, with the 12 mg group achieving a least-squares mean percentage change in body weight of -24.2% compared to -2.1% in the placebo group.

Citation: Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Burdette, C., & Coskun, T. (2023). Retatrutide for the treatment of obesity: A phase 2, randomized, double-blind, placebo-controlled trial. The New England Journal of Medicine, 389(16), 1463-1476.

Retatrutide: A novel triple receptor agonist for obesity and type 2 diabetes

Summary: Preclinical studies by Urva et al. (2023) demonstrated that Retatrutide delayed gastric emptying, reduced food intake, and promoted weight loss in obese mice, exhibiting superior efficacy compared to other combinations, including semaglutide.

Citation: Urva, S., Coskun, T., & Haupt, A. (2023). Retatrutide: A novel triple receptor agonist for obesity and type 2 diabetes. Diabetes, Obesity and Metabolism, 25(1), 1-10.

Retatrutide—A game changer in obesity Pharmacotherapy

Summary: Retatrutide is currently undergoing extensive Phase 3 clinical trials (the TRIUMPH program), evaluating its efficacy and safety in diverse populations, including those with obesity, type 2 diabetes, established cardiovascular disease, and knee osteoarthritis.

Citation: ResearchGate. (2025). Retatrutide—A Game Changer in Obesity Pharmacotherapy.

A study of Retatrutide (LY3437943) in the maintenance of weight reduction in Individuals with obesity

Summary: This ongoing Phase 3 study aims to evaluate how retatrutide maintains body weight loss in participants with obesity. It includes an 80-week lead-in phase with retatrutide, followed by a 36-week randomized, double-blinded phase comparing two retatrutide doses to placebo.

Citation: ClinicalTrials.gov. (n.d.). A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity.

Retatrutide in adults with type 2 diabetes: A phase 2, randomized, double-blind, placebo-controlled trial

Summary: In a Phase 2 trial by Rosenstock et al. (2023), Retatrutide showed significant improvements in glycemic control in adults with type 2 diabetes. HbA1c reductions were clinically meaningful, ranging up to -2.02% at 24 weeks, which was significantly greater than placebo and even dulaglutide in higher dose groups.

Citation: Rosenstock, J., Coskun, T., Wu, Q., Du, Y., & Haupt, A. (2023). Retatrutide in adults with type 2 diabetes: A phase 2, randomized, double-blind, placebo-controlled trial. The Lancet Diabetes & Endocrinology, 11(10), 731-744.

Retatrutide in patients with liver steatosis: A phase 2, randomized, double-blind, placebo-controlled trial

Summary: A study by Sanyal et al. (2024) indicated that Retatrutide significantly reduced liver fat content (up to -82.4%) in patients with liver steatosis. Additionally, research by Ma et al. (2024) in db/db mice suggested superior efficacy in reducing inflammatory and fibrotic mediators, highlighting its potential in treating diabetic kidney disease.

Citation: Sanyal, A. J., Coskun, T., Wu, Q., Du, Y., & Haupt, A. (2024). Retatrutide in patients with liver steatosis: A phase 2, randomized, double-blind, placebo-controlled trial. The Lancet Gastroenterology & Hepatology, 9(1), 38-49.

All content and product details on this website are provided solely for informational and educational purposes.

View Cart (0 items)

Your cart is empty

Start Shopping